Aethlon Medical Files S-1 Registration Statement

TL;DR

AETHLO filing S-1, looks like they're raising capital. Watch this space.

AI Summary

Aethlon Medical, Inc. filed an S-1 registration statement with the SEC on August 20, 2025. The company, incorporated in Nevada, is seeking to register securities, though the specific amount and type are not detailed in this excerpt. Aethlon Medical, Inc. is located at 11555 Sorrento Valley Road, Suite 203, San Diego, CA 92121, with a business phone number of (619) 941-0360.

Why It Matters

This S-1 filing indicates Aethlon Medical, Inc. is preparing to offer new securities to the public, which could impact its capital structure and stock availability.

Risk Assessment

Risk Level: medium — S-1 filings often precede significant corporate actions like stock offerings, which carry inherent market and financial risks.

Key Players & Entities

• AETHLON MEDICAL INC (company) — Registrant
• 0001683168-25-006352 (filing_id) — Accession Number
• 20250820 (date) — Filing Date
• 11555 Sorrento Valley Road, Suite 203, San Diego, CA 92121 (address) — Principal Executive Office
• 333-289745 (registration_number) — SEC File Number

FAQ

Key Financial Figures

• $0.0001 — [__] shares of common stock, par value $0.0001 per share ("common stock"), and accompa
• $0 — public in this Company Offering, minus $0.001, and the exercise price of each pre
• $0.001 — e of each pre-funded warrant will equal $0.001 per share of common stock. For each pre
• $1.17 — common stock as reported on Nasdaq was $1.17 per share. We are a "smaller reporting

Filing Documents

• aethlon_s1.htm (S-1) — 584KB
• aethlon_ex2301.htm (EX-23.1) — 3KB
• aethlon_ex2302.htm (EX-23.2) — 2KB
• aethlon_ex107.htm (EX-FILING FEES) — 34KB
• aethlonlogo.jpg (GRAPHIC) — 5KB
• 0001683168-25-006352.txt ( ) — 1054KB
• aemd-20250820.xsd (EX-101.SCH) — 3KB
• aemd-20250820_lab.xml (EX-101.LAB) — 33KB
• aemd-20250820_pre.xml (EX-101.PRE) — 22KB
• aethlon_s1_htm.xml (XML) — 3KB
• aethlon_ex107_htm.xml (XML) — 18KB

Risk Factors

Risk Factors 2 1 Special Note Regarding Forward-Looking Statements 25

Use of Proceeds

Use of Proceeds 27 Selling Securityholders 28

Description of Capital Stock

Description of Capital Stock 32

Description of Securities

Description of Securities 34 Certain Material U.S. Federal Tax Consequences 37 Plan of Distribution 41 Legal Matters 4 9 Experts 4 9 Market and Industry Data 4 9 Where You Can Find More Information 4 9 Incorporation of Certain Information by Reference 50 i ABOUT THIS PROSPECTUS You should read this prospectus, including the information incorporated by reference herein. Neither we, the Selling Securityholders nor the placement agent have authorized anyone to provide you with information that is different from that contained in this prospectus or in any free writing prospectus we may authorize to be delivered or made available to you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. Neither the delivery of this prospectus nor the sale of our securities means that the information contained in this prospectus or any free writing prospectus is correct after the date of this prospectus or such free writing prospectus. This prospectus is not an offer to sell or the solicitation of an offer to buy our securities in any circumstances under which the offer or solicitation is unlawful. The information contained in this prospectus is current only as of the date of this prospectus, regardless of the time of delivery of this prospectus or of any sale of our common stock or warrants. Our business, financial condition, results of operations and prospects may have changed since that date. For investors outside the United this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United of the securities covered hereby and the distr

View Full Filing

View this S-1 filing on SEC EDGAR